Oncology in Clinical Practice最新文献_第6页

Implementation of the Polish version of the 11th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-11): importance for oncology 实施《国际疾病和相关健康问题统计分类》(ICD-11)第11版波兰语版:对肿瘤学的重要性

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-06-29 DOI: 10.5603/ocp.2023.0032

Magdalena Sakowicz, B. Jagielska, L. Bodnar, Janusz Jaroszyński, Maciej Krzakowski

引用次数: 0

The effect of spirituality-based education on the meaning of life in cancer patients: a quasi-experimental study 基于灵性的教育对癌症患者生命意义的影响:一项准实验研究

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-06-15 DOI: 10.5603/ocp.2023.0034

Sajad Hamidi, N. Seyedfatemi, M. Mardani-Hamooleh, Z. Abbasi, H. Hamidi

引用次数: 0

Individualized surgical treatment in patients with advanced gastrointestinal stromal tumor — a case series 晚期胃肠间质瘤个体化手术治疗-病例系列

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-06-06 DOI: 10.5603/ocp.2023.0023

Jakub Pytlos, J. Pałucki, M. Lenarcik, Ireneusz Pierzankowski, A. Klimczak, T. Olesiński

引用次数: 0

Opinion of representatives of the psycho-oncology community on the lack of coherent systemic solutions on the legal regulation of their profession 精神肿瘤学界代表对缺乏对其职业的法律监管的连贯系统解决方案的意见

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-06-01 DOI: 10.5603/ocp.2023.0031

K. Kocańda, Michał Chrobot, M. Samardakiewicz, M. Jabłoński

{"title":"Opinion of representatives of the psycho-oncology community on the lack of coherent systemic solutions on the legal regulation of their profession","authors":"K. Kocańda, Michał Chrobot, M. Samardakiewicz, M. Jabłoński","doi":"10.5603/ocp.2023.0031","DOIUrl":"https://doi.org/10.5603/ocp.2023.0031","url":null,"abstract":"Introduction. The profession of psycho-oncologist in Poland is not sufficiently regulated by law. Current solutions in the system involve contradictory regulations on obtaining qualifications to practice, which produces in effect systemic chaos and result in limited availability of services provided to oncology patients and their families by practitioners of this demanding profession. Material and methods. A survey conducted among psycho-oncologists concerning their professional identity was used in order to examine their opinion on the current legal regulations of this profession and the possible consequences of incoherent law solutions. The study used an original anonymous questionnaire entitled Survey on selected aspects of the psycho-oncology profession in the context of its scope and method of legal regulation and the Job Satisfaction Scale questionnaire. Results. The study showed that the inconsistency in legal regulations may result in restricted access to this profession, indicated doubts concerning the legal credentials required to use the professional title of psycho-oncologist and the lack of symmetry in individual competencies of practitioners with different underlying profession. Conclusions. The research confirmed the organizational chaos which negatively affects the way psycho -on- cologists practice their profession. As a consequence the legislator intervention is required in order to modify the legal regulation of this profession.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"36 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78275445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

STANOWISKO EKSPERTÓW DOTYCZĄCE LECZENIA UZUPEŁNIAJĄCEGO OZYMERTYNIBEM CHORYCH NA NIEDROBNOKOMÓRKOWEGO RAKA PŁUCA PO RADYKALNEJ RESEKCJI NOWOTWORU

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-05-31 DOI: 10.5603/ocp.2023.0018

Renata Langford, Maciej Krzakowski, D. Kowalski, Rafał Krenke, T. Orłowski, Witold Rzyman, Bartosz Wasąg

引用次数: 0

Effects of the changes between preand post-treatment 18F-FDG PET-CT volumetric parameters on overall survival in pleural mesothelioma 治疗前后18F-FDG PET-CT体积参数变化对胸膜间皮瘤总生存率的影响

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-05-29 DOI: 10.5603/ocp.2023.0022

Faris Tüzün, S. Ebinç, M. Kaplan, İ. Kaplan, H. Kömek, Z. Oruç, Şadiye Kemal Tuzcu, B. Taşdemir

{"title":"Effects of the changes between preand post-treatment 18F-FDG PET-CT volumetric parameters on overall survival in pleural mesothelioma","authors":"Faris Tüzün, S. Ebinç, M. Kaplan, İ. Kaplan, H. Kömek, Z. Oruç, Şadiye Kemal Tuzcu, B. Taşdemir","doi":"10.5603/ocp.2023.0022","DOIUrl":"https://doi.org/10.5603/ocp.2023.0022","url":null,"abstract":"Introduction. This study aimed to examine the efficacy of positron emission tomography in fusion with computed tomography (PET-CT) parameters in predicting survival outcomes for patients with malignant pleural mesothelioma. Material and methods. This study retrospectively evaluated the data of 250 patients who were followed up after a diagnosis of malignant pleural mesothelioma. The relationship of pre-treatment [maximum standardized uptake value (SUV max1 ), metabolic tumor volume (MTV1), total lesion glycolysis (TLG1), tumor/background (TBR1), pleural thickness1), post-treatment (SUV max2 , MTV2, TLG2, TBR2, pleural thickness2], and D PET-CT parameters with survival was retrospectively evaluated in 36 patients whose pre-and post-treatment CT scan examinations were complete. Results. The median age of the patients was 57.5 years, ranging from 35 to 76. Median follow-up time was 16 months, with a range of 7 to 42 months. Median survival was calculated as 18.8 months for all patients. Based on the determined cut-off values, overall survival was determined as 29.9 months in patients with TLG2 ≤ 158 compared to 16 months in patients with TLG2 > 158 (p = 0.009) and as 30.9 months in patients with D TLG ≤ –62.58 compared to 16 months in patients with D TLG > –62.58 (p = 0.001). In addition, median overall survival (OS) was determined as 29.9 months in patients with MTV2 ≤ 63.9 compared to 16 months in patients with MTV2 > 63.9 (p = 0.007) and as 29.9 months in patients with D MTV ≤ –54.03 compared to 16 months in patients with D MTV > –54.03 (p = 0.002). When evaluated with respect to TBR2; median OS was 29.9 months in patients with TBR2 ≤ 1.84 compared to 16 months in patients with TBR2 > 1.84 (p = 0.039). Conclusions. Our research findings indicate a correlation between OS and volumetric PET-CT measures, specifically TLG and MTV.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"3 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79692553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients 泛trk免疫组化作为筛选肿瘤患者NTRK基因融合的工具

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-05-29 DOI: 10.5603/ocp.2023.0024

M. Durzyńska, I. Michalek

{"title":"Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients","authors":"M. Durzyńska, I. Michalek","doi":"10.5603/ocp.2023.0024","DOIUrl":"https://doi.org/10.5603/ocp.2023.0024","url":null,"abstract":"Therapy with TRK inhibitors is a tumor-agnostic treatment directed against specific molecular changes rather than cancer type. NTRK fusions are rare in most prevalent cancers, accounting for less than 0.5% of cases. However, there is a group of rare cancers in which NTRK fusion is more prevalent. These include secretory carcinoma of the breast and salivary gland, childhood sarcomas, such as infantile fibrosarcoma, and cellular and mixed con - genital mesoblastic nephroblastoma. The most common rearrangement pertains to NTRK3 and the most common fusion gene is ETV6 . Identifying patients with NTRK gene fusions who would likely benefit from targeted therapy with TRK inhibitors requires practical diagnostic tools and an appropriate management strategy of diagnostic trajectory. The fusions can be detected by molecular biology techniques or pan-TRK immunohistochemistry. The latter detects NTRK1/2/3 gene fusions independently of the resulting fusion gene but does not determine which of them has been rearranged or what the fusion partner is. The sensitivity and specificity of the method reach 97% and 100%, respectively. Other advantages include the relatively low cost, short duration of examination, and broad accessibility of immunohistochemistry laboratories. These characteristics make this method a useful screening tool for detecting patients with NTRK gene fusions.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"5 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91172772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pancreatic adenocarcinoma — current trends in diagnosis and treatment 胰腺腺癌——诊断和治疗的最新趋势

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-05-24 DOI: 10.5603/ocp.2023.0016

A. Gruszczyńska, Krzysztof Kowalik, K. Hetman, A. Modrzejewski

引用次数: 0

SARS-CoV-2 recurrent infections in a patient with metastatic colon cancer during chemotherapy 转移性结肠癌患者化疗期间SARS-CoV-2复发感染1例

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-05-15 DOI: 10.5603/ocp.2023.0019

Filip Zieliński, R. Wojciechowski, Joanna Terebińska, Anna Skrzypczyk-Ostaszewicz, Szymon Tomaszewski, Artur Maliborski, K. Sklinda, Hanna Cyngot, W. Solarek, Magdalena Dobosz-Foligowska, R. Duchnowska

{"title":"SARS-CoV-2 recurrent infections in a patient with metastatic colon cancer during chemotherapy","authors":"Filip Zieliński, R. Wojciechowski, Joanna Terebińska, Anna Skrzypczyk-Ostaszewicz, Szymon Tomaszewski, Artur Maliborski, K. Sklinda, Hanna Cyngot, W. Solarek, Magdalena Dobosz-Foligowska, R. Duchnowska","doi":"10.5603/ocp.2023.0019","DOIUrl":"https://doi.org/10.5603/ocp.2023.0019","url":null,"abstract":"A 72-year-old man with a metastatic KRAS gene mutated colon adenocarcinoma was admitted to the hospital for effort dyspnea and subfebrile body temperature. He was after transversostomy in 2019 and in the course of a palliative chemotherapy FOLFIRI regimen (irinotecan, calcium folinate, 5-fluorouracil) with secondary prophylaxis with filgrastim. On admission (August 2020), his general condition was quite good — Eastern Cooperative Oncology Group Performance Scale 1 (ECOG PS 1). He reported fatigue, dyspnea, partial loss of taste, and cold sweat. A polymerase chain reaction test (RT-PCR; KIT LabSystem) was positive for SARS-CoV-2 (RdRP, E, and N gene positive). In this period, the variant of the concern (VC) was primarily Wuhan SARS-CoV-2. Non-contrast computed tomography (NCCT) of the chest showed ground glass opacifications in the subpleural region, focal consolidations, and moderate pleural effusion, mostly in the lower field of the right lung (Fig. 1A, B). The patient was admitted to a single-ward hospital for the treatment of pneumonia. He received oxygen therapy, a prophylactic dose of low molecular weight heparin, ceftriaxone, and 1 unit of convalescent plasma. He finished the treatment after 13 days, obtaining the elimination of the virus confirmed by the RT-PCR test and resolution of inflammatory changes in the control NCCT (Fig. 2A, B). Due to treatment with convalescent plasma, he was not qualified for direct vaccination against SARS-CoV-2. Then, from 09/2020, due to colon cancer progression, he received the second-line palliative chemotherapy FOLFOX4 (oxaliplatin, calcium folinate, 5-fluorouracil). In April 2021, he was hospitalized in the Surgery Department to restore the continuity of the digestive tract. After the operation, the SARS-CoV-2 RT-PCR test was positive again. In this period, the British variant (Alpha)","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"34 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78013384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience 多西紫杉醇、卡铂和曲妥珠单抗新辅助治疗后her2阳性浸润性乳腺癌的病理完全缓解和生存:越南经验

IF 0.5

Oncology in Clinical Practice Pub Date : 2023-05-09 DOI: 10.5603/ocp.2023.0020

Duc Thanh Le, Tu Anh Do, Lap Thanh Bui, Kien Hung Do, C. Nguyen

{"title":"Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience","authors":"Duc Thanh Le, Tu Anh Do, Lap Thanh Bui, Kien Hung Do, C. Nguyen","doi":"10.5603/ocp.2023.0020","DOIUrl":"https://doi.org/10.5603/ocp.2023.0020","url":null,"abstract":"Introduction. Neoadjuvant chemotherapy for HER2-positive breast cancer consists of a chemotherapy regimen plus trastuzumab with or without pertuzumab. The use of trastuzumab has been shown to improve pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Purposes: To evaluate the efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) in the treatment of HER2-positive breast cancer in Vietnamese patients. Material and methods. This retrospective study reviewed stage II–III HER2-positive breast cancer patients who received neoadjuvant docetaxel, carboplatin, and trastuzumab (TCH) at the Vietnamese National Cancer Hospital. The primary endpoint was the pCR rate which was defined as the absence of invasive tumor in the breast and axil - lary nodes (ypT0/is, ypN0). The secondary endpoints were DFS, OS, and toxicities. Results. The complete and partial clinical response of 51 patients were 33.3% and 58.8%, respectively. The pCR rate was 41.2%; there was a significantly higher response in cT1-2 patients compared to cT3-4 ones (61.1% vs. 39.3%, p = 0.033). Three-year estimated DFS and OS rates were 81.3% and 93.0%, respectively. Treatment was generally well tolerated. Grade 3/4 neutropenia and anemia were uncommon (21.6% and 7.8%). No symptomatic cardiac dysfunction occurred. Conclusions. Neoadjuvant TCH, non-anthracycline chemotherapy with single anti-HER2 regimen achieved high efficacy, with a good pCR rate and favorable tolerability in stage II or III HER2-positive breast cancer patients.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"20 1","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83497005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0